key: cord-0765509-70rhygv3
authors: Einarsdottir, Sigrun; Martner, Anna; Waldenström, Jesper; Nicklasson, Malin; Ringlander, Johan; Arabpour, Mohammad; Törnell, Andreas; Wiktorin, Hanna Grauers; Nilsson, Staffan; Bittar, Rudy; Nilsson, Malin; Lisak, Mikael; Veje, Malin; Friman, Vanda; Al-Dury, Samer; Bergström, Tomas; Ljungman, Per; Brune, Mats; Hellstrand, Kristoffer; Lagging, Martin
title: Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity
date: 2022-03-16
journal: Blood Adv
DOI: 10.1182/bloodadvances.2021006937
sha: 51422279fb6b84a6b690465a3b706499b1f9d093
doc_id: 765509
cord_uid: 70rhygv3

Recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for hematological diseases are at risk of severe disease and death from COVID-19. To determine the safety and immunogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines, samples from 50 infection-naïve allo-HSCT recipients (median 92 months from transplantation, range 7–340 months) and 39 healthy controls were analyzed for serum IgG against the receptor-binding-domain (RBD) within spike 1 (S1) of SARS-CoV-2 (anti–RBD-S1 IgG) and for SARS-CoV-2–specific T-cell immunity, reflected by induction of T-cell–derived interferon-γ in whole blood stimulated ex vivo with fifteen 11-mer S1-spanning peptides. The rate of seroconversion was not significantly lower in allo-transplanted patients than controls with 24% (12/50) and 6% (3/50) of patients remaining seronegative after the first and second vaccination, respectively. However, 58% of transplanted patients lacked T-cell responses against S1 peptides after 1 vaccination compared with 19% of controls (OR 0.17; P=0.009, Fisher’s exact test) with a similar trend after the second vaccination where 28% of patients were devoid of detectable specific T-cell immunity, compared with 6% of controls (OR 0.18, P=0.02, Fisher’s exact test). Importantly, lack of T-cell reactivity to S1 peptides after vaccination heralded substandard levels (<100 BAU/ml) of anti-RBD-S1 IgG 5-6 months after the second vaccine dose (OR 8.2, P=0.007, Fisher’s exact test). We conclude that while allo-HSCT recipients achieve serum anti–RBD-S1 IgG against SARS-CoV-2 after 2 vaccinations, a deficiency of SARS-CoV-2–specific T-cell immunity may subsequently translate into insufficient humoral responses. This trial is registered at EudraCT as 2021-000349-42.

Long-term survivors after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for 3 hematological diseases frequently remain in a state of depressed T cell-mediated immunity 4 because of incomplete immune reconstitution and immunosuppressive therapy to mitigate 5 graft-versus-host disease (GvHD) 1 . Large studies report mortality rates of COVID-19 that 6 may exceed 20 % among recipients of allo-HSCT 2,3 . Hence, the risk of severe COVID-19 in 7 this patient group is considerably higher than that of the general population. Additionally, 8 immunosuppressed patients have been documented to drive the emergence and evolution of 9 new SARS-CoV-2 variants 4 further supporting the need to mitigate morbidity rates. 10 11 In healthy subjects, two doses of mRNA-based COVID-19 vaccines result in 94-95 % 12 protection against COVID-19 lasting for at least six months with similar rates of 13 seropositivity against the S1 portion of SARS-CoV-2 5, 6 . In contrast, lower seropositivity rates 14 of 68-86 % were achieved among allo-transplanted patients following two doses of the 15 BNT162b2 mRNA vaccine 7-10 , with reduced vaccine responsiveness being most prominent 16 during the first-year post-transplant 8 . Additionally, concerns exist that COVID-19 17 vaccination may elicit or worsen GvHD 7,10,11 . 18

The induction of interferon- (IFN-in whole blood samples exposed to an array of SARS-20

CoV-2 peptides ex vivo reflects virus-specific T cell immunity contributed by CD4 + and CD8 + 21 T cell subsets [12] [13] [14] . This study thus aimed at determining the humoral and cellular 22 immunogenicity of mRNA COVID-19 vaccines in long-term survivors after allo-HSCT for 23 hematological disease.

This study was conducted between March and November 2021 at the Sahlgrenska University 4

Hospital in Gothenburg, Sweden. Allo-HSCT recipients (n=58), identified in local transplant 5 registries in the Region Västra Götaland (population of approximately 1.6 million), and 6 healthy controls (n=39) were recruited to participate in this sub-study within the DurIRVac 7 study. Enrolled transplant recipients fulfilled the following pre-determined criteria: (i) to be at 8 least three months post allo-HSCT, (ii) to not have received rituximab during the last six 9 months, and (iii) to be without uncontrolled acute GvHD (grade 3-4), all according to EBMT-10 guidelines for COVID-19 vaccination (Version 2.0, December 21, 2020). 11 12 Five patients were excluded due to previous PCR-confirmed COVID-19 infection. Prior to 13 vaccination, the allo-HSCT recipients were screened for previous COVID-19 infection by 14 serology. Three additional patients were excluded because they exhibited anti-RBD-IgG. Five 15 patients showed weak T cell reactivity prior to vaccination that may indicate prior However, none of these patients were reactive against the receptor binding domain (RBD) 17 within spike 1 (S1) of SARS-CoV-2 (anti-RBD-S1 IgG) or anti-nucleocapsid IgG tests and 18

were thus regarded as infection-naive. The 50 allo-HSCT recipients included in the study 19

were intramuscularly vaccinated at a median of 41 days (range 40-50) between doses with the 20 mRNA-based SARS-CoV-2 vaccines BNT162b2 (Pfizer-BioBTech Comirnaty ® ; n=32) or 21 mRNA-1273 (Moderna Spikevax ® ; n=18) according to the standard protocol at Sahlgrenska 22 University Hospital. Peripheral blood was collected from transplant recipients at baseline, 23 before the first immunization, four weeks after the first and second vaccine doses and 4-5 24 months after the second dose. Sampling from all healthy controls was not possible prior to vaccination. However, no controls had had symptomatic COVID-19 nor had any serological 1 signs of prior infection with SARS-CoV-2. Similarly, sampling from healthy controls was not 2 available 4-5 months after the second dose. Baseline characteristics of allo-HSCT recipients 3 and healthy controls are detailed in Table 1 . Serum levels of anti-RBD-S1 IgG and the 4 magnitude of S1-specific IFN-γ responses after the first and second vaccine doses, as well as 5 their interplay were predefined primary study endpoints. 6 7 Adverse events 8

All allo-HSCT recipients completed a questionnaire following each vaccine dose. Side-effects 9

were categorized per the Common Terminology Criteria for Adverse Events standards. 10 Information about GvHD using NIH global severity score was assessed through the medical 11 notes as well as patients' self-reporting by means of questionnaire. 12

Analysis of IgG against the RBD within S1 of SARS-CoV-2 (anti-RBD-S1 IgG) 14 Chemiluminescent microparticle immunoassays were performed on serum using the 15 automated Alinity system for quantitative measurement of IgG antibodies against the RBD of 16 the spike protein of SARS-CoV-2 (SARS-CoV-2 IgG II Quant, Abbott, Abbott Park, Illinois, 17 USA) with levels reported in the WHO international standard Binding Antibody Units 18 (BAU)/mL (quantitative detection range of 14 to 5680 BAU/mL). Samples reaching 5680 19 BAU/mL were diluted with seronegative serum and reanalyzed allowing for an upper 20 detection limit of >5680 BAU/mL 15 . 21 (Sarstedt) and stimulated or not with 1 µg/mL/peptide of 15-mer peptides with 11-amino acid 1 overlap spanning the N-terminal S1 domain of the SARS-CoV-2 surface glycoprotein S1 2 (product number: 130-127-041, Miltenyi Biotec). The samples were incubated for two days at 3 37 o C with 5 % CO 2 to allow release of cytokines from peptide-responsive T cells. Thereafter, 4 tubes were centrifuged for five minutes at 1,500 rpm followed by recovery of plasma and 5 storage at -80 o C until analysis of IFN-. 6 7 IFN- ELISA 8

Plasma recovered from S1 peptide-stimulated and unstimulated whole blood samples was 9 assessed for levels of IFN-by ELISA (DY285B, R&D Systems) according to the 10 manufacturer's instructions. Plasma was diluted (1:2) in PBS containing 1% BSA and 10% 11 mouse serum (Invitrogen) to minimize unspecific reactivity. Optical density was measured at 12 450 nm and 570 nm using a FLUOstar Omega plate reader (BMG, Ortenberg, Germany). The 13 lower detection limit of the assay was 10 pg/ml. This assay was previously reported to 

Continuous variables were described as median and range, i.e., min-max values, as applicable. 2

Categorical data were described with contingency tables including frequency and percent. 3

Serological and cellular responses following vaccination, as well as differences in vaccine 4 response between allo-HSCT recipients and controls, were analyzed based on the empirical 5 distribution of 100,000 permutations of the average differences. Fisher's exact test was used 6 to calculate differences between observed frequencies in a contingency table. The association 7 between continuous parameters was determined using Spearman's correlation. The 8 association between various parameters was further determined using logistic regression. 9

Parameters with an univariate p-value <0.1 were included in multivariate analysis. 

The majority of allo-HSCT recipients developed anti-RBD-S1 IgG after COVID-19 4 vaccination ( Figure 1A ). However, 12/50 (24%) of the transplanted patients remained 5 seronegative (i.e., below the level of detection of 14 BAU/mL) after the first vaccine dose and 6 3/50 (6%) after the second. Despite two vaccine doses, 5/50 (10%) the allo-transplanted 7 patients had one month after vaccination anti-RBD-S1 IgG below 100 BAU/mL, a level above 8 which has been proposed to provide protection against COVID-19 16 . Characteristics of 9 transplant recipients achieving anti-RBD-S1 IgG below or above 100 BAU/mL despite two 10 immunizations are detailed in Table 2 , where transplantation within 24 months was 11 significantly associated with a diminished antibody response (P=0.009). 12

Although there were no significant differences regarding antibody levels between patients and 14 healthy controls after two vaccinations, the allo-HSCT recipients demonstrated a trend 15 towards delayed serological response with a larger portion below the cut-off level-of-detection 16 (<14 BAU/mL) of the assay ( Figure 1A ). Interestingly, after two vaccine doses there was a 17 considerable spread in antibody levels among allo-HSCT recipients ( Figure 1A) . A subset of 18 the transplanted patients 10/50 (20%) thus produced very high levels of anti-RBD-S1 IgG 19 (>5680 BAU/mL) following two vaccinations. None of the controls achieved similarly high 20 anti-RBD-S1 IgG levels (P=0.004, comparing the fraction of high responders among allopatients (50%) had ongoing low-grade chronic GvHD. Among the five high responders 23 without previous chronic GvHD, two developed de novo onset mild chronic GvHD after the 24 first vaccine dose. Two study patients had received rituximab because of EBV-reactivation less than 12 months (but more than 6 months) prior to inclusion in the present study. Both 1 patients were seronegative after two vaccine doses. One of the patients, however, developed T 2 cell reactivity following the second vaccine dose. 3 4 S1-specific T cell responses to COVID-19 mRNA vaccination 5 T cell responses to vaccination were assessed by measuring released IFN-γ in plasma 6 following stimulation of whole blood samples with peptides spanning the S1 region of spike 7 12 . Among allo-HSCT recipients, 29/50 (58 %) did not achieve a detectable S1-IFN-γ response 8 after one vaccine dose, and 14/50 (28 %) failed to do so also after two doses ( Figure 1B) . As 9 compared with healthy controls, patients had significantly lower S1-IFN-γ levels after both 10 the first (median 0 vs. 105 pg/mL, P=0.004, permutation test) and second (median 88 vs. 243 11 pg/mL, P=0.036, permutation test) vaccination ( Figure 1B) . The characteristics of allo-HSCT 12 recipients with undetectable virus-specific T cell responses after two vaccine doses are 13 detailed in Table 2 . No significant differences were noted for the T cell or humoral responses 14 between the 2 mRNA vaccines. 15 16

Among allo-HSCT recipients, failure to mount anti-RBD-S1 IgG after one vaccination 18 predicted failure to produce T cell-derived S1-IFN-after two vaccinations (P<0.0001, 19

Fisher's exact test). Additionally, anti-RBD-S1 IgG and S1-IFN-levels after two 20 immunizations were significantly correlated in both allo-HSCT recipients (r=0.52, P=0.001) responses were not associated in all participants. For example, after two vaccine doses 2/3 of 23 the seronegative allo-HSCT recipients showed detectable virus-specific IFN-γ induction, and 11/14 (79 %) patients with undetectable IFN-γ induction had anti-RBD-S1 IgG ≥100 1 BAU/mL. 2 3 S1-specific T cell responses in dual vaccinated individuals predict durability of serological 4 responses 5

To further elucidate the durability of the COVID-19-specific T cell and serological responses, 6 45 of the allo-HSCT recipients underwent an additional blood sampling 4-5 months after the 7 second vaccine dose (median 165 (range 114-169) days). Of note, the anti-RBD-S1 IgG levels 8 in 11/45 patients (24%) were below the proposed protective level of 100 BAU/ml 4-5 months 9

after the second vaccine dose (Figure 2 ). Among these 11 patients, 4/11 (36%) did not fulfill 10 the criteria for receiving a third dose prior to the general population. Furthermore, of the 13 11 patients with follow up samples who were devoid of a S1-specific IFN-γ response one month 12 after the second dose of vaccination, the anti-RBD-S1 IgG levels were below 100 BAU/ml 4-13 5 months later in seven individuals (54%). In contrast, among patients with specific T cell 14 responses 3-4 weeks after receiving the second vaccine dose, only 4/32 (12%) had antibody 15 levels below 100 BAU/ml (P=0.007, Fisher's exact test) 4-5 months after the second 16 immunization. Thus, the lack of a S1-specific IFN-γ response after 2 vaccine doses was 17 predictive of a suboptimal humoral response 4-5 months later, while the lack of early 18 serological response predicted lack of T cell responsiveness. Interestingly, 2 patients had a 19 detectable IFN-γ response after the second vaccine dose but lacked detectable anti-RBD-S1 20 IgG levels at any sampling throughout the study. 21 22

We performed logistic regression analyses to define the potential influence of confounders on 24 the observed differences in vaccine responses among allo-HSCT recipients and controls. In these analyses S1-IFN-γ levels were dichotomized based on below or above 10 pg/mL IFN-γ 1 in plasma supernatants or anti-RBD-S1 IgG below or above/equal to 100 BAU/mL in serum. 2

Having undergone allo-HSCT remained significantly associated with S1-IFN-γ levels <10 3 pg/mL in plasma supernatants, both after the first and second vaccine dose, when taking 4 gender, age, type of vaccine and time from second vaccination to sampling into account 5 (adjusted P-value P=0.01 after the first vaccine dose and P=0.03 after the second dose). In 6 contrast, no significant variables were found with regards to the antibody response when 7 analyzing the entire cohort including healthy controls. There were no significant differences in humoral or cellular vaccine responses among patients 4 with or without chronic GvHD. None of the patients with ongoing prednisone treatment (n=7) 5 (median dose 5mg/day, range 1.25-11mg/day) achieved detectable S1-IFN-γ levels after the 6 first vaccine dose compared with 21/43 of the patients not receiving prednisone (P=0.01, 7

Fisher's exact test). This difference was not significant following the second vaccination. 8 9

Documented COVID-19 during the study 10

One allo-HSCT recipient developed verified COVID-19 after the first vaccine dose with mild 11 symptoms not requiring treatment or hospitalization. Of note, this patient had undetectable 12 levels of anti-RBD-S1 S1 IgG as well as S1-IFN-γ after the first immunization. 13

We evaluated the safety and immunogenicity of mRNA-based COVID-19 vaccines in allo-3

HSCT survivors and noted that these vaccines were safe in these patients although mild and 4 infrequent exacerbations of chronic GvHD were observed in a similar frequency as reported 5 by others 7,10,17 . Our main finding was that while the majority of allo-transplanted patients 6 achieved serum anti-RBD-S1 IgG after two vaccinations, a deficiency of SARS-CoV-2-7 specific T cell immunity rapidly translated into lower antibody levels, below the proposed 8 protective anti-RBD-S1 IgG concentration of 100 BAU/mL. 9 10 Vaccination elicited seroconversion, reflected by detectable serum anti-RBD-S1 IgG levels, in 11 most patients. However, in one third of recipients, in particular those having undergone allo-12 HSCT within two years, humoral and/or cellular responses remained suboptimal (defined as 13 anti-RBD-S1 IgG <100 BAU/mL and/or S1-IFN-<10 pg/mL) despite two vaccine doses. A 14 deficiency in mounting a T cell response was overrepresented among patients with ongoing 15 immunosuppressive therapy. These observations confirm and extend results from previous 16 studies in which shorter time after allo-HSCT and, in some studies, ongoing 17 immunosuppressive therapy were associated with less pronounced vaccine responses [8] [9] [10] 18 . It 18 should be noted that in the present study, most patients were vaccinated several years after 19 allo-HSCT, which might have influenced the results both regarding vaccine efficacy and 20 safety. 21

It was recently recognized that immune responses to SARS-CoV-2, both infection-and 23

vaccine-induced, decline over time 19 , and that additional booster vaccine doses are likely 24 required to maintain protective immunity, in particular in immunosuppressed subjects and elderly people 20 . In addition, the recent identification of the Omicron variant challenges the 1 protective effect of vaccination against infection, although it is possible that the protection 2 against severe and possibly fatal disease might be better. Of interest, we observed that patients 3 lacking detectable T cell responses to S1 peptide four weeks after the second vaccine dose 4 were at marked risk of diminishing S1 RBD-specific antibody levels. 5 6 A seroconversion rate of 75 % was previously reported in the prospective study by Ram et al. 7

among patients having undergone allogeneic SCT or CD19-based CAR-T cell therapy 10 . In 8 this latter study, however, a subset of patients was evaluated for virus-specific T cell reactivity 9

by ELIspot, with 36 % having detectable cellular immune responses. Aside from using a 10 different method for evaluating T cell responses, it should be noted that the median time from 11 transplant was 32 months 10 , substantially shorter than in the present study. 12

In most other trials evaluating vaccine responses among recipients of allo-HSCT or solid 14 organ transplantation (SOT) 10,21 , BNT162b2 vaccinations were given with a median of 21 15 days between immunizations, per label. In our study, however, this interval was longer 16 (median 42 days) secondary to limitations in vaccine supplies as well as regional allocation 17 plans in the early phases of COVID-19 vaccine rollout. As longer intervals between doses 18 often tend to improve immune responses 22 , this may, together with that vaccinations were 19 performed late (≥ 2 years) after allo-HSCT in most (44/50) patients, have contributed to the 20 favorable antibody responses noted in the majority of participants in the present study. 21

Interestingly, vaccine-associated adverse events among allo-HSCT recipients in our study did 23 not differ from those observed in healthy controls, and no severe exacerbations of chronic 24

GvHD were observed. In the only prospective clinical trial reported in allo-transplanted patients 7 , the same type and frequency of side effects were seen in patients as in healthy 1 controls although there was a risk for significant GvHD. However, it should be noted that 2 patients in our study were at low risk for chronic GvHD declension as most enrolled patients 3 were long-time survivors after transplantation. 4 5 This study has strengths and limitations. The strengths include the parallel monitoring of 6 aspects of virus-specific B and T cell-mediated immunity as well as the complete sampling 7 performed in all enrolled patients. Although our major findings were based on observations 8 within the group of transplanted patents, a limitation of the study is the suboptimal control 9 group in which complete sampling was only available in 14 subjects. Therefore, we collected 10 further control samples from 22 staff members and their relatives at the Hematology 11 Department with samples available uniquely after two vaccinations. We thus cannot exclude 12 that some control subjects were seropositive before the first vaccination. In the present study 13 the healthy controls were older than allo-HSCT recipients, and some were sampled later after 14 immunization, which may have resulted in a greater decline of immune responses among 15 controls thus possibly overestimating the efficacy of vaccination in allo-HSCT recipients. 16 Also, importantly only two patients in the present study were vaccinated within one year of 17 allo-transplantation and the responses in these 2 patients were poor, consistent with the 18 findings in Bergman et al. 7 where patients transplanted within 12 months showed a lower 19 proportion of seroconversion. Thus, our findings might be most applicable to long-term allo-20 HSCT survivors. Additionally, to define an insufficient antibody response, we used an 21 arbitrarily chosen discriminatory anti-RBD-S1 IgG level of 100 BAU/mL. This cut-off value 22 was previously utilized as a pre-specified marker of poor response in a human therapeutic 23 SARS-CoV-2 vaccine trial 23 where antibody levels were reported in U/mL which are 24 equivalent to BAU/mL with no conversion of units required 24 . However, this threshold remains to be prospectively validated as a correlate of protection against mild or severe 1 COVID-19 and against variants of SARS-CoV-2. 2 3

In conclusion, COVID-19 mRNA vaccines are safe in long-time allo-HSCT survivors and 4 resulted in robust immune responses among the majority of patients, especially in those 5 having undergone transplantation more than two years previously. However, a subset of 6 transplanted patients showed deficient T cell responses to SARS-CoV-2 peptides that 7 heralded non-protective humoral immunity, highlighting the need for further preventive and 8 pre-emptive measures along with continued vigilance in these patients. 9 analyses. MNil collected data for healthy controls and participated in interpretation of results. 23 ML, MV, VF, and SAD participated in extracting and analysing data and interpreting results. 24 TB, PL, and MB participated in designing and writing the protocol, interpreting results, 25

writing the manuscript, and updating reference lists. All authors approved the final version of 26 the manuscript. 27 28

Conflict-of-interest disclosure: P. L. has given lectures for Pfizer and will participate in a 29 satellite symposium hosted by Moderna. The authors have nothing to disclose. 30 

controls and allo-HSCT recipients. Spike 1 (S1) specific immune responses were 4 determined in healthy controls (H.C.) and allo-HSCT recipients before vaccination (pre), after 5 the first (Vac1) or second vaccine dose (Vac2). IgG antibody levels in serum against the 6 receptor-binding domain (RBD) in S1 (A), and interferon- (IFN-production in supernatant 7 plasma following stimulation of whole blood with S1 peptides (B). The number of samples 8 below the level of detection (LOD) for each assay (anti-RBD S1 IgG <14 BAU/AU/mL and 9 S1 IFN- <10 pg/mL) is shown in brackets under each bar. Statistical comparisons were 10 calculated by empirical distribution of 100,000 permutations of the average differences. (RBD) in S1 were determined one month after the first dose of vaccination (n=50) and one 15 (n=50) and 4-5 months (n=45) after the second COVID-19 vaccine dose. Patients responsive 16 to S1-specific peptides, reflecting virus-specific T cell reactivity, at one month after the 17 second vaccine dose are shown with filled rings. Patients without a detectable S1 interferon-18 Table 1 . Baseline characteristics of allo-HSCT recipients and healthy controls. 1

Complications and risks in hematopoietic stem 3 cell transplant patients

COVID-19 and stem cell 5 transplantation; results from an EBMT and GETH multicenter prospective survey

Clinical characteristics and outcomes of

COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort 9 study

SARS-CoV-2 evolution during treatment 11 of chronic infection

Efficacy and Safety of the mRNA-13

SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 15 mRNA Covid-19 Vaccine

Safety and efficacy of the mRNA

BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and 18 healthy controls in a prospective open-label clinical trial

Response to SARS-CoV-2 vaccination in 20 patients after hematopoietic cell transplantation and CAR T-cell therapy

BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based 2 CART therapy-A Single-Center Prospective Cohort Study

An overview of infectious 5 complications after allogeneic hematopoietic stem cell transplantation

Rapid measurement of SARS-CoV-2 spike T 12 cells in whole blood from vaccinated and naturally infected individuals

Broadly directed SARS-CoV-2-specific 15

CD4+ T cell response includes frequently detected peptide specificities within the membrane 16 and nucleoprotein in patients with acute and resolved COVID-19

WHO International Standard for 19 anti-SARS-CoV-2 immunoglobulin

Correlates of protection against SARS-21

CoV-2 in rhesus macaques

Safety and Tolerability of SARS-CoV2

Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant 18

BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with 2 haematological malignancies in Lithuania: a national prospective cohort study

Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity

CDC COVID-19 Science Briefs

Waning Immune Humoral Response to

BNT162b2 Covid-19 Vaccine over 6 Months

SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

A guide to vaccinology: from basic principles to new 12 developments

Randomized Trial of a Third Dose of mRNA-14

Vaccine in Transplant Recipients

S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 17 trial. medRxiv

 Table 2 . Characteristics of allo-HSCT recipients with sufficient compared with suboptimal anti-RBD-S1 IgG (<100 BAU/mL) or non-1 detectable S1-IFN-γ after two doses of vaccinations. Anti-RBD-S1 IgG <100 BAU/mL (n=5)Anti-RBD-S1 IgG ≥100 BAU/mL (n=45) OR 3 (95% CI) Pvalue 4Interferon-γ production <10 pg/mL (n=14)Interferon-γ production ≥10 pg/mL (n=36) OR (95%CI)